Cell type variation in responses to antimitotic drugs that target microtubules and kinesin-5.
about
Live cell division dynamics monitoring in 3D large spheroid tumor models using light sheet microscopy.Kinesin-5: cross-bridging mechanism to targeted clinical therapyThe STARD9/Kif16a kinesin associates with mitotic microtubules and regulates spindle pole assemblyPharmacologic inhibition of the anaphase-promoting complex induces a spindle checkpoint-dependent mitotic arrest in the absence of spindle damageActivity of the kinesin spindle protein inhibitor ispinesib (SB-715992) in models of breast cancerQuantitative live imaging of cancer and normal cells treated with Kinesin-5 inhibitors indicates significant differences in phenotypic responses and cell fateHitting the brakes: targeting microtubule motors in cancerDNA damage associated with mitosis and cytokinesis failureMitotic Spindle Disruption by Alternating Electric Fields Leads to Improper Chromosome Segregation and Mitotic Catastrophe in Cancer Cells.Intravital FRET imaging of tumor cell viability and mitosis during chemotherapyNatural product Celastrol destabilizes tubulin heterodimer and facilitates mitotic cell death triggered by microtubule-targeting anti-cancer drugsPlk1 inhibition causes post-mitotic DNA damage and senescence in a range of human tumor cell linesSelective Aurora Kinase Inhibitors Identified Using a Taxol-Induced Checkpoint Sensitivity ScreenFine tuning chemotherapy to match BRCA1 statusAn intermittent live cell imaging screen for siRNA enhancers and suppressors of a kinesin-5 inhibitorStochastic competition between mechanistically independent slippage and death pathways determines cell fate during mitotic arrestA time-series method for automated measurement of changes in mitotic and interphase duration from time-lapse moviesVascular disrupting agent drug classes differ in effects on the cytoskeletonNecrosis, and then stress induced necrosis-like cell death, but not apoptosis, should be the preferred cell death mode for chemotherapy: clearance of a few misconceptionsRapid induction of apoptosis during Kinesin-5 inhibitor-induced mitotic arrest in HL60 cells.Prolonged mitotic arrest triggers partial activation of apoptosis, resulting in DNA damage and p53 inductionDifferential determinants of cancer cell insensitivity to antimitotic drugs discriminated by a one-step cell imaging assayMicrofluidics-integrated time-lapse imaging for analysis of cellular dynamics.Longitudinal tracking of single live cancer cells to understand cell cycle effects of the nuclear export inhibitor, selinexor.p53 suppresses structural chromosome instability after mitotic arrest in human cells.A novel synthetic 1,3-phenyl bis-thiourea compound targets microtubule polymerization to cause cancer cell death.Cell death induced by novel fluorinated taxanes in drug-sensitive and drug-resistant cancer cells.Caspase-3-mediated degradation of condensin Cap-H regulates mitotic cell deathHow Taxol/paclitaxel kills cancer cells.Curcumin-induced mitotic arrest is characterized by spindle abnormalities, defects in chromosomal congression and DNA damage.Estimating microtubule distributions from 2D immunofluorescence microscopy images reveals differences among human cultured cell linesNavitoclax (ABT-263) accelerates apoptosis during drug-induced mitotic arrest by antagonizing Bcl-xL.Caspase activity is not required for the mitotic checkpoint or mitotic slippage in human cells.Synergistic antimicrotubule therapy for prostate cancerSynthesis and characterization of tritylthioethanamine derivatives with potent KSP inhibitory activity.Blockade of autophagy aggravates endoplasmic reticulum stress and improves Paclitaxel cytotoxicity in human cervical cancer cells.The proliferation rate paradox in antimitotic chemotherapy.Design and synthesis of 2-heterocyclyl-3-arylthio-1H-indoles as potent tubulin polymerization and cell growth inhibitors with improved metabolic stability.MiRNA-149 modulates chemosensitivity of ovarian cancer A2780 cells to paclitaxel by targeting MyD88Evaluation of activity and combination strategies with the microtubule-targeting drug sagopilone in breast cancer cell lines.
P2860
Q21203549-4355063E-F639-4FDC-8AF3-027A2EF09303Q21710690-264E78B4-D5EC-4744-8116-6BF7A326475CQ24299186-CCB1EDFF-7238-4676-8450-39AE1F52868AQ24303577-A8815834-E206-414C-9EFC-96ABF929F1E0Q24615262-2442B740-509A-4B48-9248-BAAC99CB5930Q24648997-9AAA658E-CE8E-49DB-A117-A0A16B10C659Q26800271-15FB4986-E8C1-4DA8-A64A-7652D46A75BEQ26991874-E106EFB8-EEB1-493E-AE9C-A4A3CF8DAA93Q27303864-EEEC71EC-B7B8-4304-86A5-0AABCF94EFE7Q27319918-40A6A107-A539-4250-9DBB-B0513D0A82DFQ27330384-F20DCFAC-3390-46EF-90B7-25BD6901C0DFQ27334288-A0180951-C927-4F6A-A176-203E4B0F5E97Q27674986-345401FA-29A5-4259-868D-EC7BCA3F0DF6Q27694529-32F68153-A547-4DF3-9EC0-A0F6A59BE91CQ28476280-FAA1F93B-EB6C-4C35-A72C-86C849EAAB99Q28476597-B206F82F-55F1-4C15-9506-46A138988D30Q28477232-F4A51980-0793-4FC7-9DF8-10869E84F919Q28481498-9820340C-0B3F-4EB0-80BC-9F9320427C51Q28652643-13C0184B-03C6-4E89-84DC-009100B5C802Q30503448-C783AE17-5E15-4E61-A2F5-F0D8CA35B1B0Q30505355-6B4711DE-D8F4-498F-ACD6-2295A735D1BEQ30546921-E64032FA-8B93-4610-898D-918B74B20E72Q30579408-477BE7BB-F057-4A31-A14F-9A6DC3ABDF4BQ30665952-AF48131D-50B8-4E70-8F8B-6B091350ACA1Q33766312-64D8EA2A-3B39-4A48-86BE-CFD50B036F3FQ33911201-83D37AF3-4AD0-493A-93E6-20C48C11918EQ34148034-AEE55E5A-D794-4F33-896A-6F2F5D64D611Q34154598-1E3CFED2-0B13-4956-8B5E-17BC2CFC480FQ34166802-1AFC87A7-274C-46A7-9784-BB208F1F317FQ34466500-619E0A45-C6D1-47F6-A610-C56098452315Q34500094-3884B33E-1A87-4427-8EA0-B75E20640D07Q35085827-98081FCD-DCF4-48FA-B71E-308984EAFDD8Q35102610-FC6FE8B4-41E2-4E57-A373-80584965A72FQ35168819-99924C8B-EB5A-4FFF-80BE-05D1CC519C56Q35209477-6CD81EF1-9965-4B9D-BD2D-0B39296C9891Q35429855-C99A7F8A-64EA-44EC-A56F-5164A690BC9EQ35642841-2FD73595-29F2-4F9B-B060-070ED887BCF8Q35682298-143826D5-6B1C-4E21-868D-1FF2FB1C6B97Q35902797-4677D31A-C452-427E-AADC-E109E6326A8BQ35971203-A16189D1-6F18-4F0F-809C-DF50586F6B6E
P2860
Cell type variation in responses to antimitotic drugs that target microtubules and kinesin-5.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Cell type variation in respons ...... et microtubules and kinesin-5.
@en
Cell type variation in respons ...... et microtubules and kinesin-5.
@nl
type
label
Cell type variation in respons ...... et microtubules and kinesin-5.
@en
Cell type variation in respons ...... et microtubules and kinesin-5.
@nl
prefLabel
Cell type variation in respons ...... et microtubules and kinesin-5.
@en
Cell type variation in respons ...... et microtubules and kinesin-5.
@nl
P1433
P1476
Cell type variation in respons ...... get microtubules and kinesin-5
@en
P2093
Tim Mitchison
P304
P356
10.1158/0008-5472.CAN-07-6699
P407
P577
2008-05-01T00:00:00Z